Breast Cancer Trial, Recruiting NCT04344496 Sponsor: National Taiwan University Hospital Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT04344496
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 20 years of age at the time of giving consent to participate.
  • People who either have a breast tumor that has not yet been confirmed by testing, or have been confirmed through tissue testing to have invasive breast cancer.
  • People whose breast tumor measures at least 1 cm based on scans or other objective evidence.
  • People who are able to take part in the study procedures, which include providing medical information, a blood sample, a fresh tumor tissue sample, and 12 sections of tumor tissue preserved in paraffin.
  • People who are able to sign a consent form to participate in the study.

Who may not be able to join:

  • People who have been confirmed through tissue testing to have ductal carcinoma in situ (DCIS), which is a specific type of non-invasive breast condition.
  • People with early to locally advanced breast cancer (Stage I, II, or III) who have already received treatments before surgery, such as chemotherapy, hormone therapy, or targeted therapy.
  • People with advanced or spread breast cancer (Stage IV or metastatic) who have already received chemotherapy.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yen-Shen Lu, MD, PhD, National Taiwan University Hospital

Phone: +886-223123456

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
18 October 2018
Est. completion
1 October 2025

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Prevalence of unique genetic alterations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov